Insys Therapeutics Inc (NASDAQ:INSY) saw some unusual options trading activity on Thursday. Traders bought 2,156 put options on the company. This represents an increase of 1,300% compared to the typical volume of 154 put options.
Insys Therapeutics (NASDAQ:INSY) opened at $10.34 on Wednesday. Insys Therapeutics has a 12 month low of $4.10 and a 12 month high of $15.02. The stock has a market cap of $758.09, a PE ratio of -4.05 and a beta of 0.76.
Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.02). Insys Therapeutics had a negative net margin of 112.56% and a negative return on equity of 11.76%. equities analysts expect that Insys Therapeutics will post -0.63 EPS for the current year.
INSY has been the subject of a number of recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $14.00 price target on shares of Insys Therapeutics in a report on Wednesday, October 11th. Zacks Investment Research upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a report on Wednesday, October 18th. Oppenheimer restated a “hold” rating on shares of Insys Therapeutics in a report on Monday, October 30th. Jefferies Group decreased their price objective on shares of Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 3rd. Finally, ValuEngine upgraded shares of Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. Insys Therapeutics has an average rating of “Hold” and an average price target of $9.38.
TRADEMARK VIOLATION WARNING: “Stock Traders Buy Large Volume of Put Options on Insys Therapeutics (NASDAQ:INSY)” was originally published by BBNS and is the property of of BBNS. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/insys-therapeutics-target-of-unusually-high-options-trading-insy/1819742.html.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.